Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Immunology
Published in: BMC Immunology 1/2009

Open Access 01-12-2009 | Research article

High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes

Authors: Yilmaz Mahshid, Marcus-René Lisy, Xiao Wang, Rainer Spanbroek, Jenny Flygare, Birger Christensson, Magnus Björkholm, Birgitta Sander, Andreas JR Habenicht, Hans-Erik Claesson

Published in: BMC Immunology | Issue 1/2009

Login to get access

Abstract

Background

Human B lymphocytes can produce leukotriene B4 but the biological function of the 5-lipoxygenase (5-LO) pathway in B cells is unclear. In order to better understand and define the role of 5-LO in B cells, we investigated the expression of 5-LO mRNA and protein in subsets of B cells from human tonsils and different types of B cell lymphoma.

Results

Based on RT-PCR and western blot/immunohistochemical staining, with a polyclonal antibody raised against 5-LO, high expression of 5-LO was found in mantle zone B cells from tonsils. By contrast, only a weak expression of 5-LO was detected in germinal centre cells and no expression in plasma cells from tonsils. This pattern of 5-LO expression was preserved in malignant lymphoma with high expression in mantle B cell lymphoma (MCL) and weak or no expression in follicular lymphoma. Primary leukemized MCL, so called B-prolymphocytic leukaemia cells, and MCL cell lines also expressed 5-LO and readily produced LTB4 after activation.

Conclusion

The present report demonstrates the expression of 5-LO mainly in normal and malignant mantle zone B cells while the expression is low or absent in germinal centre B cells and plasma cells, indicating a role of the 5-LO pathway in B cells before the cells finally differentiate to plasma cells.
Appendix
Available only for authorised users
Literature
1.
Claesson HE, Dahlen SE: Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J Intern Med. 1999, 245 (3): 205-227.CrossRefPubMed
2.
Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000, 275 (39): 30531-30536.CrossRefPubMed
3.
Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateauneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DL, Ford-Hutchinson AW, Caskey CT, Evans JF: Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999, 399 (6738): 789-793.CrossRefPubMed
4.
Tager AM, Luster AD: BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003, 69 (2–3): 123-134.CrossRefPubMed
5.
Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, Ferrario S, Parravicini C, Capra V, Gelosa P, Guerrini U, Belcredito S, Cimino M, Sironi L, Tremoli E, Rovati GE, Martini C, Abbracchio MP: The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. Embo J. 2006, 25 (19): 4615-4627.PubMedCentralCrossRefPubMed
6.
Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ: Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980, 286 (5770): 264-265.CrossRefPubMed
7.
Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH: Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol. 2003, 4 (10): 965-973.CrossRefPubMed
8.
Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ: Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol. 2003, 4 (10): 974-981.CrossRefPubMed
9.
Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, Friedrich EB, Carafone AD, Gerszten RE, Luster AD: Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol. 2003, 4 (10): 982-990.CrossRefPubMed
10.
Claesson HE, Odlander B, Jakobsson PJ: Leukotriene B4 in the immune system. Int J Immunopharmacol. 1992, 14 (3): 441-449.CrossRefPubMed
11.
Yamaoka KA, Dugas B, Paul-Eugene N, Mencia-Huerta JM, Braquet P, Kolb JP: Leukotriene B4 enhances IL-4-induced IgE production from normal human lymphocytes. Cell Immunol. 1994, 156 (1): 124-134.CrossRefPubMed
12.
Rola-Pleszczynski M: Differential effects of leukotriene B4 on T4+ and T8+ lymphocyte phenotype and immunoregulatory functions. J Immunol. 1985, 135 (2): 1357-1360.PubMed
13.
Jakobsson PJ, Steinhilber D, Odlander B, Radmark O, Claesson HE, Samuelsson B: On the expression and regulation of 5-lipoxygenase in human lymphocytes. Proc Natl Acad Sci USA. 1992, 89 (8): 3521-3525.PubMedCentralCrossRefPubMed
14.
Jakobsson PJ, Shaskin P, Larsson P, Feltenmark S, Odlander B, Aguilar-Santelises M, Jondal M, Biberfeld P, Claesson HE: Studies on the regulation and localization of 5-lipoxygenase in human B-lymphocytes. Eur J Biochem. 1995, 232 (1): 37-46.CrossRefPubMed
15.
Werz O, Steinhilber D: Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells. The presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. Eur J Biochem. 1996, 242 (1): 90-97.CrossRefPubMed
16.
Runarsson G, Liu A, Mahshid Y, Feltenmark S, Pettersson A, Klein E, Bjorkholm M, Claesson HE: Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood. 2005, 105 (3): 1274-1279.CrossRefPubMed
17.
Woods JW, Coffey MJ, Brock TG, Singer II, Peters-Golden M: 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J Clin Invest. 1995, 95 (5): 2035-2046.PubMedCentralCrossRefPubMed
18.
Brock TG, McNish RW, Bailie MB, Peters-Golden M: Rapid import of cytosolic 5-lipoxygenase into the nucleus of neutrophils after in vivo recruitment and in vitro adherence. J Biol Chem. 1997, 272 (13): 8276-8280.CrossRefPubMed
19.
Brock TG, Paine R, Peters-Golden M: Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells. J Biol Chem. 1994, 269 (35): 22059-22066.PubMed
20.
Luo M, Jones SM, Flamand N, Aronoff DM, Peters-Golden M, Brock TG: Phosphorylation by protein kinase a inhibits nuclear import of 5-lipoxygenase. J Biol Chem. 2005, 280 (49): 40609-40616.CrossRefPubMed
21.
Werz O, Klemm J, Radmark O, Samuelsson B: p38 MAP kinase mediates stress-induced leukotriene synthesis in a human B-lymphocyte cell line. J Leukoc Biol. 2001, 70 (5): 830-838.PubMed
22.
Jaffe ES, H NL, Stein H, Vardiman JW: World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. 2001, Lyon: WHO
23.
Leonard JP, Schattner EJ, Coleman M: Biology and management of mantle cell lymphoma. Curr Opin Oncol. 2001, 13 (5): 342-347.CrossRefPubMed
24.
Walsh SH, Thorselius M, Johnson A, Soderberg O, Jerkeman M, Bjorck E, Eriksson I, Thunberg U, Landgren O, Ehinger M, Lofvenberg E, Wallman K, Enblad G, Sander B, Porwit-MacDonald A, Dictor M, Olofsson T, Sundstrom C, Roos G, Rosenquist R: Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood. 2003, 101 (10): 4047-4054.CrossRefPubMed
25.
Islam TC, Asplund AC, Lindvall JM, Nygren L, Liden J, Kimby E, Christensson B, Smith CI, Sander B: High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia. 2003, 17 (9): 1880-1890.CrossRefPubMed
26.
Feltenmark S, Runarsson G, Larsson P, Jakobsson PJ, Bjorkholm M, Claesson HE: Diverse expression of cytosolic phospholipase A2, 5-lipoxygenase and prostaglandin H synthase 2 in acute pre-B-lymphocytic leukaemia cells. Br J Haematol. 1995, 90 (3): 585-594.CrossRefPubMed
27.
Spanbroek R, Hildner M, Steinhilber D, Fusenig N, Yoneda K, Radmark O, Samuelsson B, Habenicht AJ: 5-lipoxygenase expression in dendritic cells generated from CD34(+) hematopoietic progenitors and in lymphoid organs. Blood. 2000, 96 (12): 3857-3865.PubMed
28.
Frater JL, Hsi ED: Properties of the mantle cell and mantle cell lymphoma. Curr Opin Hematol. 2002, 9 (1): 56-62.CrossRefPubMed
29.
Hsi ED, Frater JL: Advances in the diagnosis and classification of chronic lymphoproliferative disorders. Cancer Treat Res. 2004, 121: 145-165.CrossRefPubMed
30.
Jakobsson PJ, Odlander B, Steinhilber D, Rosen A, Claesson HE: Human B lymphocytes possess 5-lipoxygenase activity and convert arachidonic acid to leukotriene B4. Biochem Biophys Res Commun. 1991, 178 (1): 302-308.CrossRefPubMed
31.
Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007, 7 (10): 750-762.CrossRefPubMed
32.
Cook-Moreau JM, El-Makhour Hojeij Y, Barriere G, Rabinovitch-Chable HC, Faucher KS, Sturtz FG, Rigaud MA: Expression of 5-lipoxygenase (5-LOX) in T lymphocytes. Immunology. 2007, 122 (2): 157-166.PubMedCentralCrossRefPubMed
33.
Werz O, Tretiakova I, Michel A, Ulke-Lemee A, Hornig M, Franke L, Schneider G, Samuelsson B, Radmark O, Steinhilber D: Caspase-mediated degradation of human 5-lipoxygenase in B lymphocytic cells. Proc Natl Acad Sci USA. 2005, 102 (37): 13164-13169.PubMedCentralCrossRefPubMed
34.
Rimokh R, Berger F, Bastard C, Klein B, French M, Archimbaud E, Rouault JP, Santa Lucia B, Duret L, Vuillaume M: Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood. 1994, 83 (12): 3689-3696.PubMed
35.
Grammer AC, McFarland RD, Heaney J, Darnell BF, Lipsky PE: Expression, regulation, and function of B cell-expressed CD154 in germinal centers. J Immunol. 1999, 163 (8): 4150-4159.PubMed
36.
Spanbroek R, Stark HJ, Janssen-Timmen U, Kraft S, Hildner M, Andl T, Bosch FX, Fusenig NE, Bieber T, Radmark O, Samuelsson B, Habenicht AJ: 5-Lipoxygenase expression in Langerhans cells of normal human epidermis. Proc Natl Acad Sci USA. 1998, 95 (2): 663-668.PubMedCentralCrossRefPubMed
Metadata
Title
High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes
Authors
Yilmaz Mahshid
Marcus-René Lisy
Xiao Wang
Rainer Spanbroek
Jenny Flygare
Birger Christensson
Magnus Björkholm
Birgitta Sander
Andreas JR Habenicht
Hans-Erik Claesson
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2009
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-10-2

Other articles of this Issue 1/2009

BMC Immunology 1/2009 Go to the issue

Research article

Selenoproteins regulate macrophage invasiveness and extracellular matrix-related gene expression

Research article

Variable expression of cysteinyl leukotriene type I receptor splice variants in asthmatic females with different promoter haplotypes

Research article

Tumor necrosis factor-alpha induced expression of matrix metalloproteinase-9 through p21-activated Kinase-1

Research article

Chemokines are secreted by monocytes following OK-432 (lyophilized Streptococcus pyogenes) stimulation

Research article

The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection

Research article

Biochemical analysis of CTLA-4 immunoreactive material from human blood
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits